Naver Third-Quarter Net Profit Rises 54% on Year
By Kwanwoo Jun
Naver third-quarter net profit rose 54% from a year earlier, led by strong growth in its e-commerce, paid-content and cloud-computing businesses.
Net profit for the quarter ended September was 356.20 billion Korean won ($266.9 million) compared with net profit of KRW231.60 billion in the same quarter a year ago, the South Korean internet platform group said Friday.
That beat a FactSet-compiled consensus forecast for net profit of KRW288.94 billion.
Revenue during the quarter rose 19% from a year earlier to KRW2.445 trillion, with operating profit gaining 15% year-over-year to KRW380.20 billion.
The company said its e-commerce, paid-content and cloud-computing units drove the strong quarterly revenue growth. Those segments grew a pace of 30% to 41% from a year earlier in the quarter.
Search-platform advertisements edged up 3.5% while display advertisements declined 9.5% in the quarter, compared with a year ago, amid weakness in the online advertising market, it said.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
November 02, 2023 20:04 ET (00:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks